Show simple item record

Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec

dc.contributor.authorSoysal, Teoman
dc.contributor.authorEskazan, Ahmet Emre
dc.contributor.authorSadri, Sevil
dc.contributor.authorAyer, Mesut
dc.contributor.authorKantarcioglu, Bulent
dc.contributor.authorDemirel, Naciye
dc.contributor.authorAydin, Demet
dc.contributor.authorAydinli, Fuat
dc.contributor.authorYokus, Osman
dc.contributor.authorTuzuner, Nukhet
dc.contributor.authorOzunal, Isil Erdogan
dc.contributor.authorYalniz, Fevzi Firat
dc.contributor.authorKeskin, Dilek
dc.contributor.authorAydin, Yildiz
dc.contributor.authorAr, Muhlis Cem
dc.contributor.authorElverdi, Tugrul
dc.contributor.authorBerk, Selin
dc.contributor.authorOngoren, Seniz
dc.contributor.authorSalihoglu, Ayse
dc.contributor.authorBaslar, Zafer
dc.contributor.authorOzbek, Ugur
dc.date.accessioned2021-03-05T20:58:22Z
dc.date.available2021-03-05T20:58:22Z
dc.date.issued2017
dc.identifier.citationEskazan A. E. , Sadri S., Keskin D., Ayer M., Kantarcioglu B., Demirel N., Aydin D., Aydinli F., Yokus O., Ozunal I. E. , et al., "Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec", CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.17, ss.804-811, 2017
dc.identifier.issn2152-2650
dc.identifier.otherav_d6b40db3-362d-477b-90f2-0fd237bf44e4
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/141684
dc.identifier.urihttps://doi.org/10.1016/j.clml.2017.07.255
dc.description.abstractWe retrospectively evaluated 90 patients with chronic myeloid leukemia receiving either upfront original imatinib (Ol) or generic imatinib (Gl) for the effect of the early molecular response on the long-term outcome. We demonstrated that achieving an optimal response at 3 and 6 months in patients receiving either first-line Gl or Ol was clearly associated with greater response and event-free survival rates.
dc.language.isoeng
dc.subjectONKOLOJİ
dc.subjectOnkoloji
dc.subjectHematoloji
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectHEMATOLOJİ
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.titleOutcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec
dc.typeMakale
dc.relation.journalCLINICAL LYMPHOMA MYELOMA & LEUKEMIA
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume17
dc.identifier.issue12
dc.identifier.startpage804
dc.identifier.endpage811
dc.contributor.firstauthorID247956


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record